10% Off
Dabixta75 mg
Unimed Unihealth MFG. Ltd.
৳67.50
Add to cart
Generic medicine
Dabigatran Etexilate Mesylate: Brands, Price & Uses in Bangladesh
Dabigatran Etexilate Mesylate is a direct thrombin inhibitor (an oral anticoagulant) used to reduce the risk of blood clots and stroke.
About Dabigatran Etexilate Mesylate
Indications of Dabigatran Etexilate Mesylate
Dabigatran Etexilate Mesylate is a direct thrombin inhibitor (an oral anticoagulant) used to reduce the risk of blood clots and stroke. Its uses can be classified by strength of evidence as follows:
FDA-approved (established) indications
- Stroke and systemic embolism prevention in non-valvular atrial fibrillation (NVAF) — to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) — in adult patients who have been treated with a parenteral (injectable) anticoagulant for 5 to 10 days.
- Reduction in the risk of recurrence of DVT and PE — in adult patients who have previously received treatment.
- Treatment of venous thromboembolism (VTE) and reduction in risk of VTE recurrence in pediatric patients — in appropriate age groups, after at least 5 days of initial parenteral anticoagulation (see Pediatric Uses).
Guideline-supported / internationally approved uses
- Primary prevention of venous thromboembolism after major orthopedic surgery (e.g., elective hip or knee replacement surgery) — this indication is approved and guideline-supported in several countries outside the United States, though it is not a US FDA-labeled indication for Dabigatran Etexilate Mesylate.
Note: Dabigatran Etexilate Mesylate is not indicated for patients with mechanical prosthetic heart valves (see Contraindications), and is not used as an antiplatelet agent for acute coronary syndromes.
Dosage & Administration of Dabigatran Etexilate Mesylate
Dosing by indication (adults, normal to mild renal impairment unless stated)
| Indication | Recommended dose | Notes |
|---|---|---|
| Stroke/systemic embolism prevention in NVAF (CrCl >30 mL/min) | 150 mg orally twice daily | Assess renal function before starting and periodically thereafter |
| NVAF, CrCl 15-30 mL/min | 75 mg orally twice daily | Dose reduced based on pharmacokinetic modeling |
| NVAF, CrCl <15 mL/min or on dialysis | Not recommended | No dosing recommendation can be provided; avoid use |
| Treatment of DVT/PE (CrCl >30 mL/min) | 150 mg orally twice daily | After 5-10 days of initial treatment with a parenteral anticoagulant |
| Reduction of recurrence of DVT/PE | 150 mg orally twice daily | In patients previously treated for VTE |
| DVT/PE treatment or recurrence-reduction, CrCl ≤30 mL/min | Not recommended | Not studied; avoid use |
Renal function should be assessed in all patients before starting Dabigatran Etexilate Mesylate and re-evaluated periodically during treatment, particularly in elderly patients or those with intercurrent illness that may affect kidney function. See Interaction and Precautions sections for dose considerations with concomitant P-glycoprotein (P-gp) inhibitors or inducers.
Side Effects of Dabigatran Etexilate Mesylate
The most common adverse effects of Dabigatran Etexilate Mesylate relate to bleeding and gastrointestinal tolerability.
Common side effects
- Dyspepsia (indigestion, upper abdominal discomfort), gastritis-like symptoms, and abdominal pain.
- Bleeding events of varying severity, including epistaxis (nosebleeds), gastrointestinal bleeding, bruising, and hematuria (blood in urine).
- Nausea.
Serious side effects (seek urgent medical attention)
- Major or life-threatening bleeding (e.g., severe gastrointestinal bleeding, intracranial hemorrhage) — signs include unusual bruising, pink/brown urine, red/black stools, coughing up blood, or severe unexplained weakness.
- Signs of spinal or epidural hematoma in patients undergoing spinal procedures (see Precautions and Warnings).
- Signs of hypersensitivity/anaphylaxis (rash, swelling of face/throat, difficulty breathing).
Contraindications of Dabigatran Etexilate Mesylate
Dabigatran Etexilate Mesylate is contraindicated in patients with:
- Active pathological bleeding.
- Known serious hypersensitivity (e.g., anaphylaxis) to dabigatran or any component of Dabigatran Etexilate Mesylate.
- Mechanical prosthetic heart valves — Dabigatran Etexilate Mesylate is contraindicated in this population; clinical trial data showed an increased risk of thrombotic events (including valve thrombosis, stroke, and myocardial infarction) and increased bleeding compared with warfarin.
Frequently Asked Questions about Dabigatran Etexilate Mesylate
What is Dabigatran Etexilate Mesylate used for?
Dabigatran Etexilate Mesylate is a direct thrombin inhibitor (blood thinner) used to reduce the risk of stroke in people with non-valvular atrial fibrillation, and to treat and prevent recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).
How should I take Dabigatran Etexilate Mesylate?
Swallow the capsule whole with a full glass of water; do not open, break, or chew it, as this changes how quickly the drug is absorbed and can increase bleeding risk. It can be taken with or without food, exactly as prescribed, usually twice daily.
Can I stop taking Dabigatran Etexilate Mesylate on my own if I feel fine?
No. Stopping Dabigatran Etexilate Mesylate without your physician's guidance increases the risk of blood clots and stroke. If treatment needs to be paused (for example, before surgery), your physician will advise on timing and whether an alternative anticoagulant is needed.
Who should not take Dabigatran Etexilate Mesylate?
Dabigatran Etexilate Mesylate should not be used by people with active serious bleeding, known hypersensitivity to the drug, or a mechanical prosthetic heart valve, as it has been shown to increase the risk of clot formation on the valve and other thrombotic events in that specific group compared with warfarin.
What should I do if I notice unusual bleeding or bruising while taking Dabigatran Etexilate Mesylate?
Contact your physician promptly, or seek emergency care if bleeding is severe (e.g., black or bloody stools, coughing up blood, severe headache). Dabigatran Etexilate Mesylate increases bleeding risk, and a specific reversal agent (idarucizumab) is available in hospital settings for serious bleeding emergencies.
Is Dabigatran Etexilate Mesylate safe during pregnancy or breastfeeding?
Safety data are limited. Dabigatran Etexilate Mesylate should be used in pregnancy only if clearly needed, and a physician should be consulted about breastfeeding, since it is not well established whether the drug passes into breast milk in significant amounts.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.